Ironwood Pharmaceuticals Ownership
| IRWD Stock | USD 1.49 0.08 5.67% |
Shares in Circulation | First Issued 2008-12-31 | Previous Quarter 160.2 M | Current Value 160.2 M | Avarage Shares Outstanding 132.1 M | Quarterly Volatility 45 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ironwood |
Ironwood Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company last dividend was issued on the 2nd of April 1970. Ironwood Pharmaceuticals had 1194:1000 split on the 2nd of April 2019. Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. To learn more about Ironwood Pharmaceuticals call the company at 617 621 7722 or check out https://www.ironwoodpharma.com.Besides selling stocks to institutional investors, Ironwood Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ironwood Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ironwood Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ironwood Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Only 1.8% of Ironwood Pharmaceuticals are currently held by insiders. Unlike Ironwood Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ironwood Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ironwood Pharmaceuticals' insider trades
Ironwood Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ironwood Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ironwood Pharmaceuticals backward and forwards among themselves. Ironwood Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ironwood Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 3.6 M | Geode Capital Management, Llc | 2024-12-31 | 3.3 M | Millennium Management Llc | 2024-12-31 | 2.2 M | Ubs Group Ag | 2024-12-31 | 2.2 M | Charles Schwab Investment Management Inc | 2024-12-31 | 2 M | Northern Trust Corp | 2024-12-31 | 1.6 M | Deutsche Bank Ag | 2024-12-31 | 1.6 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.2 M | Jupiter Asset Management Limited | 2024-12-31 | 1.2 M | Blackrock Inc | 2024-12-31 | 23 M | Vanguard Group Inc | 2024-12-31 | 19.5 M |
Ironwood Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ironwood Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ironwood Pharmaceuticals Outstanding Bonds
Ironwood Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ironwood Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ironwood bonds can be classified according to their maturity, which is the date when Ironwood Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.